Literature DB >> 18840031

Preventing Alzheimer's disease : separating fact from fiction.

Mary Sano1, Hillel Grossman, Kathleen Van Dyk.   

Abstract

Alzheimer's disease is an ever-increasing health concern among the aging population, and as we research new and existing treatments for this disease we begin to uncover possibilities for its prevention. Observational studies and animal models have provided promising findings and generated excitement, but placebo-controlled clinical trials are required to demonstrate true efficacy for these treatments.In the past two decades, clinical trials have led to the approval of symptomatic treatments for Alzheimer's disease, including cholinesterase inhibitors and, more recently, an NMDA receptor antagonist. Clinical trials have also examined antioxidants, NSAIDs, hormone replacement, nutritional supplements and nonpharmacological interventions for the treatment and prevention of Alzheimer's disease. While the results of many of these trials have been disappointing, new mechanisms targeting the hallmark pathology of Alzheimer's disease are currently under investigation, including immunotherapy and secretase modulation, targeted at reducing the amyloid burden, for which we await the results. We review the evidence from completed trials, support for ongoing studies and propose directions for future research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18840031     DOI: 10.2165/00023210-200822110-00001

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  130 in total

1.  Midlife blood pressure and dementia: the Honolulu-Asia aging study.

Authors:  L J Launer; G W Ross; H Petrovitch; K Masaki; D Foley; L R White; R J Havlik
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

2.  Effects of lovastatin and pravastatin on cognitive function in military aircrew.

Authors:  M G Gibellato; J L Moore; K Selby; E A Bower
Journal:  Aviat Space Environ Med       Date:  2001-09

3.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

4.  Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.

Authors:  Tobias Engel; Félix Hernández; Jesús Avila; José J Lucas
Journal:  J Neurosci       Date:  2006-05-10       Impact factor: 6.167

5.  Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study.

Authors:  Eric G Rodriguez; Hiroko H Dodge; Maria A Birzescu; Gary P Stoehr; Mary Ganguli
Journal:  J Am Geriatr Soc       Date:  2002-11       Impact factor: 5.562

6.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

7.  Thiamine therapy in Alzheimer's disease.

Authors:  Y Mimori; H Katsuoka; S Nakamura
Journal:  Metab Brain Dis       Date:  1996-03       Impact factor: 3.584

8.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

9.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment.

Authors:  Ihab Hajjar; Jeannie Schumpert; Victor Hirth; Darryl Wieland; G Paul Eleazer
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-07       Impact factor: 6.053

10.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

Authors:  Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

View more
  6 in total

1.  Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Michael L Niehoff; John E Morley; Albert M Crider; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2010-12-24       Impact factor: 4.432

2.  Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints.

Authors:  Eric A Macklin; Deborah Blacker; Bradley T Hyman; Rebecca A Betensky
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

3.  Lost in translation: epidemiology, risk, and Alzheimer disease.

Authors:  Mary Ganguli; Walter A Kukull
Journal:  Arch Neurol       Date:  2010-01

Review 4.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

5.  Effects of fermented ginseng on memory impairment and β-amyloid reduction in Alzheimer's disease experimental models.

Authors:  Joonki Kim; Sung Hun Kim; Deuk-Sik Lee; Dong-Jin Lee; Soo-Hyun Kim; Sungkwon Chung; Hyun Ok Yang
Journal:  J Ginseng Res       Date:  2013-03       Impact factor: 6.060

6.  The neuritogenic and neuroprotective potential of senegenin against Aβ-induced neurotoxicity in PC 12 cells.

Authors:  Robert Jesky; Hailong Chen
Journal:  BMC Complement Altern Med       Date:  2016-01-23       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.